Sinocelltech
CompanyChina
Sinocelltech develops one asset, in phase 1 (SCT520FF in nAMD). Mostly antibody; based in China.
- 1
- Asset
- Furthest stage
- Phase 1
- 21
- Trials
- 0
- Signals
Pipeline
1Inhibits VEGF-mediated angiogenesis in the retina.
Phase 1, Antibody, nAMD
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials23
- Integrity notices1
- Similar companies6